Prosecution Insights
Prosecution Insights
Technology area: Medical Devices & Mechanical Engineering
3 pending office actions • 1 art units • 1 examiners • 0 of 3 (0%) have an AI response strategy ready
Precise-Bio 3D Ltd. operates a patent portfolio in Biotechnology & Pharmaceuticals. There is 1 pending office action currently active. This 1 pending office action is handled by 1 distinct examiner and is located within 1 distinct art unit, reflecting a concentrated area of current examination. The 1 pending office action represents the entirety of the company's current examiner-led prosecution workload within this technology area.
PYLA, EVELYN Y is the busiest examiner for this portfolio, with 1 busiest examiner pending office action. This figure matches the total 1 pending office action for the company. This indicates that the company's current prosecution efforts are entirely managed by PYLA, EVELYN Y. For the practitioner, this means that the prosecution outcome for the company is dependent on the review of this 1 distinct examiner. Strategy should be developed with a focus on the specific technical requirements of the 1 distinct art unit and the individual examination style of PYLA, EVELYN Y.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLASS, PARIS MARIE | 3 | 54.5% | +39.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17766670 | BIOENGINEERED CORNEAL GRAFTS | BLASS, PARIS MARIE | 22d |
| 18392866 | BIOENGINEERED CORNEAL GRAFTS | BLASS, PARIS MARIE | — |
| 18088673 | BIOENGINEERED CORNEAL GRAFTS | BLASS, PARIS MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17766670 | BIOENGINEERED CORNEAL GRAFTS | BLASS, PARIS MARIE | 22d |
| 18392866 | BIOENGINEERED CORNEAL GRAFTS | BLASS, PARIS MARIE | — |
| 18088673 | BIOENGINEERED CORNEAL GRAFTS | BLASS, PARIS MARIE | — |
| Art Unit | Apps |
|---|---|
| 3774 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18392866 | BIOENGINEERED CORNEAL GRAFTS | BLASS, PARIS MARIE | 3774 | §102§103 | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18088673 | BIOENGINEERED CORNEAL GRAFTS | BLASS, PARIS MARIE | 3774 | §102§103§112 | Non-Final OA | — | Pending | Dec 26, 2022 |
| 17766670 | BIOENGINEERED CORNEAL GRAFTS | BLASS, PARIS MARIE | 3774 | §102§103 | Final Rejection | 22d | Pending | Apr 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial